Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹176.9 Cr
verified against source
Revenue YoY
23.6%
reported change
EBITDA
₹45.2 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
RPG Life Sciences delivered a strong Q4 FY26 with revenue of 176.9 cr (+23.6% YoY) and EBITDA of 45.2 cr (+48% YoY), driven by domestic formulation growth of 18.2% (1.8x IPM) and a sharp recovery in API (Q4 revenue 33.3 cr). The domestic business outpaced the market on volume growth (9% vs 1.1%), while new introductions contributed 5.1%. Management guided for sustained mid-teens domestic growth, API as a growth driver with a pipeline of 13 molecules, and international formulation returning to growth post inventory normalization. Key risks include potential raw material cost inflation from geopolitical tensions and regulatory delays in export markets.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to maintain historical domestic growth trajectory of ~12% driven by volume and new launches.
- API growth expected to sustain at 9-10% with a strong pipeline of 13 products and expansion into new markets.
- Post inventory normalization, international business expected to revert to historical 9-15% growth trajectory.
- Three of five CDMO projects expected to start generating revenue in FY27, two in FY28.
Risks flagged
- Management noted monitoring of West Asia war developments; prices locked for 6 months but escalation could impact margins.
- International formulation segment faced regulatory delays in host countries, impacting performance.
- Management indicated USFDA approval is deferred until a significant product basket is ready, citing high costs and shifting dynamics.
Key quotes
- Our revenue from operations grew by 23.6% along with 48% increase in EBITDA and 58.1% increase in PAT excluding exceptional items.
- We have a very clear road map on this on what exactly we need to do. We quantify the exposure with clear triggers, confirm where we stand today, and summarize the mitigation actions already under way.
- We would actually seek approval only when there is a significant basket of product with strong market share in the US... the company is also mindful of the cost benefit equation.
Research modules